ICARE Genetics Case Conference: Defining Actionable Risk Thresholds in HBOC & Beyond (June 2026)
Keywords
Summary
165 words
Critical Evaluation
Value of the Information & Strength of the Argument
The presentation provides substantial value by translating complex health economic concepts into actionable clinical thresholds. Dr. Manchanda’s argumentation is robust, grounded in published research and ongoing studies, including cost-effectiveness models and acceptability surveys. He clearly explains the methodology behind threshold determination, making a compelling case for a continuous risk-based approach over binary genetic testing results. The discussion of specific thresholds for different cancers and interventions is well-supported by data, though some thresholds are still under investigation.
Scientific Rigor, Source Quality, Title Accuracy
The talk demonstrates high scientific rigor, with references to peer-reviewed publications in journals like JAMA Oncology and the Journal of the National Cancer Institute. Dr. Manchanda cites specific studies and guidelines, including those from NICE and ACMG, and acknowledges ongoing research and uncertainties. The title accurately reflects the content, focusing on defining actionable risk thresholds. The presentation is well-structured, with clear explanations of health economic terms and their application to clinical practice.
163 words
Title / Content Match
The title accurately reflects the content, focusing on defining actionable risk thresholds in hereditary breast and ovarian cancer and beyond.
Quality & Reliability
8/10
Presentation by a leading expert in gynecological oncology, based on published research and ongoing studies, with clear methodology and references to peer-reviewed journals.
Chapters
Cited Sources
- ICARE on Bluesky — Social media handle for ICARE, mentioned in the video description.
- ICARE on LinkedIn — LinkedIn page for ICARE, mentioned in the video description.
Concurring Sources
- JAMA Oncology publication on risk-reducing mastectomy thresholds — Referenced by Dr. Manchanda as the source for the 35% lifetime risk threshold for mastectomy.
Contribution & Novelties
This presentation offers a comprehensive overview of how risk thresholds for preventive interventions in hereditary cancers are determined using health economic modeling. It provides a novel framework that integrates cost-effectiveness with clinical acceptability, moving beyond traditional binary genetic risk categories. The discussion of specific thresholds for ovarian, breast, and endometrial cancers, and the inclusion of emerging strategies like risk-reducing salpingectomy, adds valuable insights for clinicians and researchers.
Pour aller plus loin :
- Quality-adjusted life year (QALY) — A key concept in health economics used to measure the value of medical interventions.
- Incremental cost-effectiveness ratio (ICER) — A metric used to compare the cost-effectiveness of different interventions.
- CanRisk — A web-based tool for breast and ovarian cancer risk prediction, mentioned in the case discussion.
123 words
Radar Profile
The radar profile shows high scores in quality of information and technical level, reflecting the expert-led, research-based content. The quantity of information is also substantial, though the presentation is more focused on synthesis than on presenting new primary data. The overall reliability is high, supported by references to peer-reviewed literature.